IMPACT Therapeutics, Inc. (HKG: 7630) and Pharmanovia announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization for Sepalna (senaparib) in the maintenance treatment of advanced epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | CHMP / EMA (European Union) |
| Opinion Type | Positive opinion recommending marketing authorization |
| Product | Sepalna (senaparib) |
| Indication | Maintenance treatment of advanced epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer |
| Opinion Date | 20 Sep 2026 |
| Prior Approvals | China (NMPA, Jan 2025) – first‑line maintenance in advanced ovarian/fallopian tube/primary peritoneal cancer post platinum response; added to National Reimbursement Drug List (Dec 2025) |
| Next Steps | Final European Commission marketing authorization decision |
Clinical Evidence – Pivotal Phase III FLAMES Study
| Endpoint | Result (Senaparib) | Comparator (Placebo) | Relative Benefit |
|---|---|---|---|
| Median Progression‑Free Survival (interim analysis) | Not yet reached | 13.6 months | Mature PFS pending |
| Risk of Disease Progression or Death | HR = 0.43 (95% CI 0.32–0.58; p<0.0001) | – | 57 % risk reduction |
| Benefit Across BRCA Status | Efficacy regardless of BRCA mutation status | – | Consistent across homologous recombination subgroups |
The FLAMES study evaluated senaparib versus placebo as first‑line maintenance therapy in patients with advanced (FIGO Stage III–IV) high‑grade epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who achieved a complete or partial response to first‑line platinum‑based chemotherapy. In the broad advanced ovarian cancer population, senaparib as first‑line maintenance monotherapy reduced the risk of disease progression or death regardless of BRCA mutation status, with consistent benefit across homologous recombination subgroups.
Drug Profile & Mechanism of Action
- Molecule: Senaparib – a novel, highly active PARP1/2 inhibitor, independently developed by IMPACT Therapeutics.
- Class Positioning: Oral PARP inhibitor for first‑line maintenance in advanced ovarian cancer – the broadest‑label setting in the class, supported by biomarker‑agnostic benefit in FLAMES.
- Regulatory Track Record: Approved by China’s NMPA in January 2025 for first‑line maintenance after platinum response; included in China’s National Reimbursement Drug List in December 2025, securing nationwide patient access and reimbursement.
Partnership Structure & Market Impact
- Exclusive Collaboration: Under the July 2026 agreement, IMPACT Therapeutics granted Pharmanovia exclusive rights to manufacture, develop, and commercialize senaparib in 66 countries for maintenance monotherapy in advanced epithelial high‑grade ovarian cancer, fallopian tube cancer, and primary peritoneal cancer.
- Territory Coverage: The licensed footprint includes all 27 EU member states, plus the United Kingdom, Norway, Iceland, Switzerland, Liechtenstein, Australia, New Zealand, and countries across the Middle East and North Africa.
- EU Market Entry: A positive CHMP opinion positions Sepalna to compete in the European first‑line PARP‑maintenance market, where biomarker‑agnostic efficacy is a key differentiator for broad patient reach.
- Global Franchise Momentum: With China approval plus NRDL reimbursement secured and EU authorization imminent, senaparib is transitioning from a domestic asset into a global ovarian‑cancer franchise, with Pharmanovia leading ex‑China commercialization across licensed territories.
- Commercial Terms: Deal financial terms and launch timing – not disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding regulatory decisions, clinical outcomes, partnership execution, and commercial expectations for senaparib (Sepalna). A positive CHMP opinion does not guarantee a final European Commission marketing authorization. Actual results may differ due to risks including regulatory review outcomes, manufacturing and supply‑chain execution, market adoption, competitive dynamics in the PARP inhibitor class, and reimbursement negotiations across licensed territories.-Fineline Info & Tech
